June 20, 2024Open Access

Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase

Key Points

Key points are not available for this paper at this time.

Abstract

The FDA's alerts regarding the T-cell lymphoma risk post CAR-T therapy has garnered global attention, yet a comprehensive profile of second primary malignancies (SPMs) following CAR-T treatment is lacking.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Shen et al. (Thu,) studied this question.

synapsesocial.com/papers/68e63e25b6db6435875d007d https://doi.org/https://doi.org/10.1016/j.eclinm.2024.102684

Bookmark

View Full Paper